A four-marker blood test combines established CA19-9 and THBS2 with two newly identified proteins, ANPEP and PIGR, which show elevated levels in early-stage pancreatic cancer.

The panel offers the advantage of distinguishing pancreatic cancer from non-cancerous pancreatic conditions like pancreatitis, reducing misdiagnosis and unnecessary concern.

Experts stress the need for larger, prediagnostic studies to evaluate screening potential, especially for high‑risk individuals with a family history, genetic factors, or prior pancreatic conditions.

The research is supported by multiple NIH grants, underscoring strong federal backing for this work.

Relying on CA19-9 and THBS2 alone has limitations, since CA19-9 can be elevated in non-cancer conditions and some people do not produce CA19-9, reducing reliability.

In validation, the four-marker panel correctly distinguished cancer cases from non-cases 91.9% of the time across all stages, with a 5% false-positive rate, and 87.5% sensitivity for early-stage cancers (stages I/II).

If validated, this four-marker panel could improve early detection of pancreatic ductal adenocarcinoma and potentially improve treatment outcomes through earlier intervention.